The stock NASDAQ:SAVA is consolidating in a triangle and shows relative strength in the past few days. It might happen soon, that the stock will break through the upper boundary of the triangle which will lead the way towards 11$ and later also 15$.
Looks like SAVA is going to move up - good time to get in at 8.26 - 8.28. NASDAQ:SAVA
Cassava Sciences (SAVA) just got some positive clinical trial data on their Alzheimer’s drug. The result caused one analyst firm to upgrade SAVA’s price target from $3.00 per share to $6.00 per share. SAVA’s got a 9.4/10 analyst summary score, with most analysts rating the stock a “buy.” I entered SAVA Friday morning at $2.16 per share. It’s already up almost 100%...
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX. SHORT INTEREST 1.64M 08/30/19 P/E Current -2.07 P/E Ratio...